Back
10-K2026-04-13· merged:deepseek-v4-flash

KOPN · Kopin Corporation

0001493152-26-016338

SEC filing

Summary

Kopin reported a 22% revenue decline in FY2025, driven by defense sales, but reduced net loss indicates operational progress.

Key takeaways

Full analysis

Period Performance

Period Performance

Kopin Corporation's MD&A for FY2025 highlights a 22% decline in total revenues compared to FY2024, driven primarily by lower sales in the defense segment. The company attributes this to an intentional strategic shift to focus on higher-margin opportunities and diversify its customer base. Despite the revenue drop, the company reports a reduced net loss, signaling operational improvements and cost control measures. Management notes that progress toward profitability continues, though no specific net loss or EPS figures were disclosed in the MD&A section.

Segment Dynamics

The MD&A does not provide a detailed segment-level financial breakdown. However, it references that defense sales accounted for 74% of total revenue in FY2025, down from 82% in the prior year, reflecting the company's pivot to industrial, medical, and other markets. The industrial and medical segments showed growth, while consumer revenue remained negligible. Funded research and development contracts (primarily U.S. government) contributed 12% of total revenues, consistent with FY2024.

Forward View

Kopin's MD&A outlines several strategic priorities: expanding its ASOS (application-specific optical solutions) offerings, advancing MicroLED display technology through government awards (e.g., a $15.4M IBAS contract), and strengthening its European manufacturing base via Kopin Europe. The company expects to continue investing in R&D even at the expense of near-term profitability. Cash position improved significantly to $61.6 million as of December 27, 2025, following a $38.1 million private placement in late 2025. Management expresses confidence in future growth but cautions about geopolitical risks, supply chain dependencies, and the need for positive cash flow.

Note: Detailed financial metrics such as gross profit, operating income, and earnings per share were not explicitly disclosed in the MD&A section provided; thus, they are omitted from this analysis.